Insight and its relationship to clinical outcomes in patients with schizophrenia or schizoaffective disorder receiving long-acting risperidone

International Clinical Psychopharmacology

Volumn 21, Issue 4, 2006, Pages 233-240

  Gharabawi, Georges M ^a   Lasser, Robert A ^a   Bossie, Cynthia A ^a   Zhu, Young ^a   Amador, Xavier ^b  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Insight; Long acting risperidone; Quality of life; Schizoaffective disorder; Schizophrenia

Indexed keywords

RISPERIDONE;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; CHRONIC DRUG ADMINISTRATION; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; INTROSPECTION; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; PATIENT COMPLIANCE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SHORT FORM 36; SYMPTOMATOLOGY; THOUGHT DISORDER; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES; PSYCHOTIC DISORDERS; QUALITY OF LIFE; REGRESSION ANALYSIS; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 33646680982     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200607000-00006     Document Type: Article

References (33)

1. Aguglia E, De Vanna M, Onor ML, Ferrara D (2002). Insight in persons with schizophrenia: effects of switching from conventional neuroleptics to atypical antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 26:1229-1233.
2. Amador XF, Gorman JM (1998). Psychopathologic domains and insight in schizophrenia. Psychiatr Clin North Am 21:27-42.
3. Amador XF, Strauss DH, Yale SA, Gorman JM (1991). Awareness of illness in schizophrenia. Schizophr Bul 17:113-132.
4. Amador XF, Strauss DH, Yale S, Gorman JM, Endicott J (1993). Assessment of insight in psychosis. Am J Psychiatry 150:873-879.
5. Amador XF, Flaum M, Andreasen NC, Strauss DH, Yale SA, Clark SC, et al. (1994). Awareness of illness in schizophrenia and schizoaffective and mood disorders. Arch Gen Psychiatry 51:826-836.
6. American Psychiatric Association (1994). Diagnostic and statistical manual of mental disorders, 4th edn. Washington, DC: American Psychiatric Association.
7. Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B, et al. (2002). Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 159:1018-1028.
8. Csernansky JG, Mahmoud R, Brenner R (2002). A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 346:16-22.
9. Fleischhacker WW, Eerdekens M, Karcher K, Remington G, Llorca PM, Chrzanowski W, et al. (2003). Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 64:1250-1257.
10. Guy W (1976). ECDEU Assessment manual for psychopharmacology, revised, 1976. Publication ADM 76-338. Rockville, Maryland: National Institute of Mental Health, US Department of Health and Human Services, pp. 218-222.
11. Honey GD, Bullmore ET, Soni W, Varatheesan M, Williams SC, Sharma T (1999). Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia. Proc Natl Acad Sci USA 9:13432-13437.
12. Kay SR, Fiszbein A, Opler LA (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261-276.
13. Kemp RA, Lambert TJ (1995). Insight in schizophrenia and its relationship to psychopathology. Schizophr Res 18:21-28.
14. Keshavan MS, Rabinowitz J, DeSmedt G, Harvey PD, Schooler N (2004). Correlates of insight in first episode psychosis. Schizophr Res 70:187-194.
15. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV (2002). Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 63:892-909.
16. Lasser R, Bossie CA, Gharabawi G, Eerdekens M, Nasrallah HA (2004). Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder. J Affect Disord 83:263-275.
17. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209-1223.
18. Marder SR, Davis JM, Chouinard G (1997). The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 58:538-546.
19. Miller DD, Andreasen NC, O'Leary DS, Watkins GL, Boles Ponto LL, Hichwa RD (2001). Comparison of the effects of risperidone and haloperidol on regional cerebral blood flow in schizophrenia. Biol Psychiatry 49:704-715.
20. Mintz AR, Dobson KS, Romney DM (2003). Insight in schizophrenia: a meta-analysis. Schizophr Res 61:75-88.
21. Moore O, Cassidy E, Carr A, O'Callaghan E (1999). Unawareness of illness and its relationship with depression and self-deception in schizophrenia. Eur Psychiatry 14:264-269.
22. Nakano H, Terao T, Iwata N, Hasako R, Nakamura J (2004). Symptomatological and cognitive predictors of insight in chronic schizophrenia. Psychiatry Res 127:65-72.
23. Pallanti S, Quercioli L, Pazzagli A (1999). Effects of clozapine on awareness of illness and cognition in schizophrenia. Psychiatry Res 86:239-249.
24. Pini S, Dell'Osso L, Amador XF, Mastrocinque C, Saettoni M, Cassano GB (2003). Awareness of illness in patients with bipolar I disorder with or without comorbid anxiety disorders. Aust NZ J Psychiatry 37:355-361.
25. Sajatovic M, Rosch DS, Sivec HJ, Sultana D, Smith DA, Alamir S, et al. (2002). Insight into illness and attitudes toward medications among inpatients with schizophrenia. Psychiatr Serv 53:1319-1321.
26. Schwartz RC (1998). Insight and illness in chronic schizophrenia. Compr Psychiatry 39:249-254.
27. Schwartz RC, Cohen BN, Grubaugh A (1997). Does insight affect long-term impatient treatment outcome in chronic schizophrenia? Compr Psychiatry 38:283-288.
28. Sevy S, Nathanson K, Visweswaraiah H, Amador X (2004). The relationship between insight and symptoms in schizophrenia. Compr Psychiatry 45:16-19.
29. Smith CM, Barzman D, Pristach CA (1997). Effect of patient and family insight on compliance of schizophrenic patients. J Clin Pharmacol 37:147-154.
30. Smith TE, Hull JW, Santos L (1998). The relationship between symptoms and insight in schizophrenia: a longitudinal perspective. Schizophr Res 33:63-67.
31. Smith TE, Hull JW, Israel LM, Willson DF (2000). Insight, symptoms, and neurocognition in schizophrenia and schizoaffective disorder. Schizophr Bull 26:193-200.
32. Ware JKJr, Sherbourne CD (1992). The MOS 36-item health survey Med Care 30:473-483.
33. Yen CF, Chen CS, Ko CH, Yeh ML, Yang SJ, Yen JY, et al. (2005). Relationships between insight and medication adherence in outpatients with schizophrenia and bipolar disorder: prospective study. Psychiatry Clin Neurosci 59:403-409.